Literature DB >> 31239118

Insomnia and hot flashes.

Enrica Bonanni1, Alessandro Schirru2, Maria Caterina Di Perri3, Ubaldo Bonuccelli2, Michelangelo Maestri2.   

Abstract

The increased prevalence of sleep disorders associated with menopause has been emphasized by multiple international studies. Many factors are associated with insomnia during menopause, among them: hot flashes (HF), anxiety and depression, other medical conditions, behavioral and psychosocial factors and primitive sleep patterns. The domino hypothesis connects various factors and suggests that HF disturb sleep, thereby causing insomnia, which in turn increases vulnerability to depression. Nevertheless, sleep disorders predict mood disturbances more robustly than vasomotor symptoms (VMS), indicating that sleep also influences mood via other mechanisms. The medical conditions that may compromise sleep in this age group are common; they include obesity, gastroesophageal reflux, cancer, urinary incontinence and nocturia, thyroid dysfunction, chronic pain, fibromyalgia (often starting or worsening in menopause), and hypertension. Common causes of sleep disorders in middle-aged women include poor sleep hygiene, volitional factors, environmental disturbances, alcohol intake, marital dissatisfaction, requests for care from children, grandchildren and/or elderly parents, and financial worries. Evidence from other populations suggests that if insomnia is not treated, it may negatively affect the outcome of comorbid conditions. Taken together, these observations suggest that insomnia should be considered a disorder requiring specific attention and treatment. Moreover, recent cross-sectional data link sleep with subclinical markers of cardiovascular risk. It should also be noted that insomnia is common in patients with mild to moderate obstructive sleep apnea syndrome (OSAS).
Copyright © 2019 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Hot flashes; Insomnia; Menopause; Sleep

Mesh:

Year:  2019        PMID: 31239118     DOI: 10.1016/j.maturitas.2019.05.001

Source DB:  PubMed          Journal:  Maturitas        ISSN: 0378-5122            Impact factor:   4.342


  6 in total

Review 1.  Nocturia through the menopausal transition and beyond: a narrative review.

Authors:  Kim Pauwaert; An-Sofie Goessaert; Lynn Ghijselings; Thomas F Monaghan; Herman Depypere; Karel Everaert
Journal:  Int Urogynecol J       Date:  2021-01-13       Impact factor: 2.894

2.  Tuina for perimenopausal insomnia: A protocol for systematic review and meta-analysis.

Authors:  Xiaoyu Zhi; Hongshi Zhang; Yangshengjie Liu; Ye Zhang; Jiabao Sun; Xuewei Zhao; Yuesong Yang; Peng Liu
Journal:  Medicine (Baltimore)       Date:  2022-01-14       Impact factor: 1.817

3.  Environmental Stressors Suffered by Women with Gynecological Cancers in the Aftermath of Hurricanes Irma and María in Puerto Rico.

Authors:  Pablo A Méndez-Lázaro; Yanina M Bernhardt; William A Calo; Andrea M Pacheco Díaz; Sandra I García-Camacho; Mirza Rivera-Lugo; Edna Acosta-Pérez; Naydi Pérez; Ana P Ortiz-Martínez
Journal:  Int J Environ Res Public Health       Date:  2021-10-25       Impact factor: 3.390

Review 4.  Global hotspots and prospects of perimenopausal depression: A bibliometric analysis via CiteSpace.

Authors:  Mingzhou Gao; Hao Zhang; Zhan Gao; Ya Sun; Jieqiong Wang; Fengqin Wei; Dongmei Gao
Journal:  Front Psychiatry       Date:  2022-09-10       Impact factor: 5.435

5.  Agomelatine, A Potential Multi-Target Treatment Alternative for Insomnia, Depression, and Osteoporosis in Postmenopausal Women: A Hypothetical Model.

Authors:  Ahmet Yardimci; Mehmet Ridvan Ozdede; Haluk Kelestimur
Journal:  Front Psychiatry       Date:  2021-06-29       Impact factor: 4.157

6.  Hot flashes, insomnia, and the reproductive stages: a cross-sectional observation of women from the EPISONO study.

Authors:  Helena Hachul; Laura Siqueira Castro; Andréia Gomes Bezerra; Gabriel Natan Pires; Dalva Poyares; Monica Levy Andersen; Lia Rita Bittencourt; Sergio Tufik
Journal:  J Clin Sleep Med       Date:  2021-11-01       Impact factor: 4.062

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.